癌患者のCOVID-19ワクチン接種に対するユーモラル免疫反応 - ANRS0001S COV-POPART研究の結果

Liem Binh Luong Nguyen¹, Lyvia Magloire², Alexis François²

¹INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Centre d'Investigation Clinique Cochin Pasteur, Paris, France; Université de Paris, Paris, France.

Vaccine

|August 23, 2025

まとめ

癌患者は初期にCOVID-19ワクチンの反応が弱かったが,ブースター投与後に同様の免疫力を獲得した. これは,がん患者を含む免疫不全患者のブースター注射の利点を強調しています.

科学分野:

免疫学
腫瘍学
ワクチン学

背景:

がん患者には,ワクチンに対する免疫反応が低下することが多い.
最初のCOVID-19ワクチン接種シリーズの後,がん患者にはブースター投与が推奨されます.
がん患者のワクチン免疫性を理解することは公衆衛生にとって極めて重要です.

研究の目的:

ガン患者と健康な成人の間でCOVID-19ワクチンのユーモラル免疫性を比較する.
ワクチン接種と再接種後の免疫反応を評価する.
SARS-CoV-2 変種に対する抗体レベルと中和能力の評価.

主な方法:

前向きコホート研究 (ANRS0001S COV- POPART) には,以前のSARS-CoV-2感染のない75歳未満のワクチン接種を受けた参加者が含まれています.
抗SARS-CoV-2 IgG抗体の幾何学平均タイター (GMT) と中和抗体の測定は,プライマリーシリーズ後1ヶ月,ブースター後1ヶ月と6ヶ月です.
183人のがん患者と1173人の健康な対照群の比較

主要な成果:

がん患者は,プライマリー・シリーズ後にIgG濃度が低かった (GMT 132. 4 vs 332. 7 BAU/ ml).
ブースター投与後,がん患者は対照群と比較して1ヶ月 (GMT 2146. 1 vs 1841. 3 BAU/ mL) と6ヶ月 (602. 0 vs 574. 4 BAU/ mL) で同様のIgGレベルを達成しました.
中和抗体のレベルは,これらの発見を裏付けました.

結論:

ブースター投与は,がん患者におけるCOVID-19ワクチンの免疫性を著しく高めます.
癌患者は,ブースター投与後1ヶ月と6ヶ月で比較可能な免疫反応を示します.
この結果は,がん患者に対する再接種の推奨と効果を裏付けています.

キーワード:

ブースターコロナウイルス免疫性ワクチン癌について

さらに関連する動画

07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

1.9K

06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.4K

関連する概念動画

01:30

Cancer Vaccines

509

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

509

01:36

Humoral Immune Responses

Rous Sarcoma Virus (RSV) and Cancer

5.4K

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

5.4K

01:27

Tumor Immunotherapy

660

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccinations

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...